source
- Boehringer Ingelheim to seek approval for obesity injection survodutide after trial shows no added cardiovascular riskBoehringer Ingelheim announced it will file for regulatory approval of its investigational GLP-1 based obesity injection, survodutide, in the coming year. The move follows a phase 3 trial that dem…
- Novo and Novartis see heart drug setbacks as trials show minimal efficacyNovo's cardiovascular candidate failed to demonstrate meaningful benefit in its pivotal study, causing the company's shares to fall about 9% in July. The trial data showed the drug had little effe…